ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0036376;sodium ion export across plasma membrane;9.0;1.0;0.896240625180289;9.628524252492122;131.16583792001737;7.138016298065211;0.004390002553592762;0.7612791106150483;[ATP1B2, ATP1B1, SLC8A1]
GO:0002001;renin secretion into blood stream;9.0;1.0;0.896240625180289;9.628524252492122;133.331941423656;9.083926447120524;0.004462500088492957;0.8607930461318132;[SUCNR1]
GO:0071380;cellular response to prostaglandin E stimulus;8.0;1.0;0.875;9.628524252492122;704.3614414198233;6.943860283624253;0.023574343560179453;0.7301093378270707;[P2RY6, AKT1]
GO:0003333;amino acid transmembrane transport;9.0;0.5756379274792419;0.68405958891991;8.302854513188667;195.84914281057607;5.500407508664414;0.006554894557084751;0.6775317209684948;[SLC1A3, SLC38A11, SLC7A11, SLC38A6, SLC36A1, SLC6A6, SLC7A8]
GO:0002003;angiotensin maturation;8.0;1.0;0.875;9.628524252492122;184.72117518317427;7.379178354882098;0.00618245149511628;0.7523715242355574;[ACE, MME, CTSG]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, PROK2, MAP4K1, MAP2K2, DUSP6, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, PKN1]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[LRRK2, F2R, ADAM9]
GO:0097647;amylin receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;55.74562497482455;7.9853141584524145;0.0018657559001020701;0.7592887026755414;[RAMP1]
GO:0050435;amyloid-beta metabolic process;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;60.01596331221528;6.943860283624253;0.0020086802811995464;0.6782296504172152;[ACE, MME, PSEN2, APEH]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[NRP1, NRP2, HMGB2, CDH3, AKT1, GHSR, ARG1, MMP12, C5AR1, TGFA, IQGAP3, TGFB1, EGR3, NR4A1, LRG1]
GO:0036486;ventral trunk neural crest cell migration;8.0;1.0;0.875;9.628524252492122;24.653414450138296;8.67846133901236;8.251275950136018E-4;0.8188169164668168;[NRP1]
GO:0061684;chaperone-mediated autophagy;6.0;1.0;0.8231203125901445;9.628524252492122;237.71007808667926;8.67846133901236;0.007955942388380075;0.7669372290569613;[LAMP2]
GO:0060355;positive regulation of cell adhesion molecule production;5.0;1.0;0.7902410118609202;9.628524252492122;40.679961272662325;8.390779266560578;0.0013615216942077584;0.7193458537639684;[COLEC12]
GO:0061444;endocardial cushion cell development;5.0;1.0;0.7902410118609202;9.628524252492122;34.232648149996464;9.777073627680469;0.0011457359261972313;0.7902410118609202;[JAG1]
GO:2000251;positive regulation of actin cytoskeleton reorganization;9.0;1.0;0.896240625180289;9.628524252492122;130.7363647434596;6.8867018697843045;0.004375628472874139;0.7484268790654467;[NRP1, STAP1]
GO:1900025;negative regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;367.370684139938;7.212124270218933;0.012295566186013157;0.7438283705770736;[TACSTD2, ACTN4]
GO:0048009;insulin-like growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.138016298065211;0.0010376185600805164;0.7400384854347593;[CRIM1, AKT1, TSC2]
GO:0048008;platelet-derived growth factor receptor signaling pathway;8.0;0.7763722522362496;0.7631861261181248;9.186691500213083;31.002284443533863;6.280566066213989;0.0010376185600805164;0.6961884407023742;[NRP1, PDGFC]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[DOCK5, NRP1, OLFM4, DNM2, FLNA]
GO:1900028;negative regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;173.84791521056468;8.16763571524637;0.005818533269131697;0.8139338954918922;[TACSTD2, STAP1]
GO:0048012;hepatocyte growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.292166977892469;0.0010376185600805164;0.747921758369865;[NRP1, STMN1]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[CYFIP1, NRP1, NRP2, NCF4, PTK2]
GO:0051894;positive regulation of focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;280.4986055833795;6.599019797332524;0.009388035896519984;0.712474179321389;[NRP1]
GO:0070392;detection of lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;133.13119460921556;9.777073627680469;0.0044557812732740395;0.8231203125901445;[TREM2]
GO:0071360;cellular response to exogenous dsRNA;7.0;1.0;0.8509193652572005;9.628524252492122;172.52541059605554;7.069023426578259;0.005774270229860956;0.7124295520356204;[COLEC12]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[AP2M1, MMP9, EPHA3, SDC2, LYN, PTK2]
GO:0030816;positive regulation of cAMP metabolic process;10.0;0.8259837884571596;0.8282329060895002;9.526741558182179;1396.5025295312637;6.139487467954083;0.04673968289273128;0.7292146864874571;[LHCGR, RAMP1, TSHR]
GO:2000484;positive regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.069023426578259;0.02521906460756386;0.7767511986393403;[F2R, TLR1, CD2, FFAR2, CD58]
GO:0060385;axonogenesis involved in innervation;9.0;1.0;0.896240625180289;9.628524252492122;65.99544162831262;8.16763571524637;0.0022088080392582156;0.8139338954918922;[NRP1]
GO:1902336;positive regulation of retinal ganglion cell axon guidance;12.0;1.0;0.9481203125901445;9.628524252492122;1458.3969986044274;9.083926447120524;0.04881123507120434;0.9126727335416687;[NRP1]
GO:0150020;basal dendrite arborization;10.0;1.0;0.9152410118609203;9.628524252492122;197.41096074002914;8.67846133901236;0.006607167197638665;0.8590579283277371;[NRP1]
GO:0042953;lipoprotein transport;8.0;1.0;0.875;9.628524252492122;68.44752614357394;7.138016298065211;0.0022908771012512216;0.7400384854347593;[MSR1, LRP1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, F13A1, LAMP2, ACTN1, ANXA5, ACTN4, F5, TLN1, STXBP2, FLNA, LYN, TGFB1, LHFPL2, CD9]
GO:0002455;humoral immune response mediated by circulating immunoglobulin;7.0;1.0;0.8509193652572005;9.628524252492122;48.293467131004675;8.390779266560578;0.001616338883576055;0.7800242071602487;[EXO1, HLA-DQB1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[FGF5, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SLC8A1, SCN1A, ATP1B2, ATP1B1, SGK1, SLC22A4, SLC24A1, SLC24A4, SLC38A11, SLC38A6, SLC4A7, SLC6A6]
GO:0002456;T cell mediated immunity;5.0;0.7586651285174919;0.6695735761196662;9.117698628726131;29.48574010893193;6.250713103064308;9.868611860026806E-4;0.609902770639515;[DENND1B, JAG1, IL18RAP]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, TGFA, FGF5, RACGAP1, NUP62, PDGFC, SVIL, TGFB1, CDC6, CIT, BTC]
GO:0098712;L-glutamate import across plasma membrane;12.0;0.9326813400603323;0.9144609826203107;9.600353375525426;1074.08790550917;7.9853141584524145;0.03594875558103501;0.8564896500084854;[SLC1A3]
GO:0006816;calcium ion transport;8.0;0.6696747006330769;0.7098373503165385;8.690254613899192;35.67391733828006;4.3132418226548594;0.001193973908871026;0.5955793873968269;[DENND5B, SLC8A1, CTGF, F2R, CACNA2D3, CALCRL, PSEN2, CORO1A, ATP2A3, SLC24A1, SLC24A4, RAMP1]
GO:2000134;negative regulation of G1/S transition of mitotic cell cycle;9.0;0.7980440201809971;0.7952626352707877;9.394909401310617;355.88113835876356;5.244474134527214;0.011911021428637128;0.6644432763129993;[CDKN1A, PCNA, GPNMB, NACC2, SFN, E2F7, PLK2, CNOT3, EZH2]
GO:0051549;positive regulation of keratinocyte migration;9.0;1.0;0.896240625180289;9.628524252492122;297.9389118084288;7.697632086000634;0.009971747250615804;0.7898978880348613;[ADAM9, MMP9, HBEGF]
GO:2000391;positive regulation of neutrophil extravasation;10.0;1.0;0.9152410118609203;9.628524252492122;703.074040491935;8.16763571524637;0.023531255409708643;0.8329342821725234;[IL1R1]
GO:0033077;T cell differentiation in thymus;7.0;0.8653626801206646;0.7836007053175329;9.420884887713877;66.99450330244977;6.481236761676141;0.002242245734394454;0.6823701146576509;[BCL11B, FZD5, CCR6]
GO:0060019;radial glial cell differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;23.145667324477426;7.292166977892469;7.746646556020492E-4;0.6631627702307852;[GPR157]
GO:1903556;negative regulation of tumor necrosis factor superfamily cytokine production;6.0;0.7866048967936545;0.7164227609869718;9.186691500213083;65.65969381209598;5.885253329569843;0.002197570862002862;0.6240924415566148;[CD274, ORM1, GPNMB, GHSR, BPI, GPR18, LTF]
GO:1904886;beta-catenin destruction complex disassembly;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.7325511899570465;0.0012734203321220245;0.6345439928109722;[FZD5, PPP1CA]
GO:1901018;positive regulation of potassium ion transmembrane transporter activity;10.0;0.7671156992804218;0.7987988615011312;9.418803721510052;727.157729141708;6.7325511899570465;0.02433731479490395;0.7595439928109722;[ATP1B2, ATP1B1, DNM2]
GO:0002588;positive regulation of antigen processing and presentation of peptide antigen via MHC class II;7.0;1.0;0.8509193652572005;9.628524252492122;143.84822124462497;9.083926447120524;0.004814470510063408;0.8154717862087246;[TREM2]
GO:0006702;androgen biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;272.3789533364416;7.379178354882098;0.00911627844302757;0.728290889492758;[SRD5A3]
GO:0030913;paranodal junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;88.99224575364705;7.8311634786251565;0.00297849037755313;0.7236063770733796;[CD9]
GO:0140009;L-aspartate import across plasma membrane;12.0;1.0;0.9481203125901445;9.628524252492122;681.8170375248549;9.083926447120524;0.022819802650461112;0.9126727335416687;[SLC1A3]
GO:2000146;negative regulation of cell motility;6.0;0.5781283279524737;0.6121844765663813;8.01908634005802;116.39406446339459;4.247644540169047;0.0038956045897326065;0.5403450519100613;[SPINT2, DACH1, MEF2C, PADI2, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, PTPRR, MCTP1, PTPRK, ARAP3, ENG, LRP1]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[NRP1, HMGB2, LGALS3, AKT1]
GO:0002281;macrophage activation involved in immune response;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;81.79914540449643;7.379178354882098;0.0027377437822370863;0.7004918368257019;[SUCNR1]
GO:0006883;cellular sodium ion homeostasis;9.0;1.0;0.896240625180289;9.628524252492122;285.76071857591336;6.8867018697843045;0.009564154082785858;0.7484268790654467;[ATP1B2, ATP1B1, SLC8A1]
GO:0006520;cellular amino acid metabolic process;6.0;0.406884124246779;0.526562374713534;6.526182243879872;77.81072980309767;4.002522082136061;0.0026042551013992716;0.5278094780068945;[KMO, SLC1A3, SLC6A6, HAL, NOX4, ARG1, SLC7A8]
GO:0002042;cell migration involved in sprouting angiogenesis;9.0;1.0;0.896240625180289;9.628524252492122;27.169092758590633;7.069023426578259;9.093250840340128E-4;0.757750811958709;[NR4A1, NRP1, EGR3]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[, NUP107, AKT1, NUP85, NUP88, MMP12, CSE1L, LAMP2, AP2M1, RAB32, SLC27A2, BCL6, NLGN1, UNC93B1, EGR2, POLA2, CD24, XPO1, TMED6, STX11, RANBP1, NUPL2, RAMP1, TSC2, ATP1B1, HGS, TGFB1, NUP155, NUP62, NUP133, TBC1D9, NUP54, NUP35, RAN]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, CXCL16, LGALS3, EDNRB, CCRL2, C3AR1, CXADR, S100A8, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, EGR3, AZU1, DEFA1, NR4A1, NRP1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, CCR6, RHOG, GAB1, HBEGF, CXCR5, CXCR4, CXCR1, CXCR2]
GO:0006879;cellular iron ion homeostasis;10.0;0.8436909121759173;0.837086467948879;9.474373572664863;186.73793370626092;5.69953618377475;0.006249950587919157;0.706715557354699;[TFRC, SLC40A1, LCN2, LTF]
GO:0031954;positive regulation of protein autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;6.481236761676141;0.026061291479152104;0.7466917612613706;[ACE, GPNMB, PDGFC]
GO:0051604;protein maturation;5.0;0.5930994877375815;0.586790755729711;7.613621231949857;47.85814540089318;4.401795219996305;0.001601769057033345;0.5153490241159427;[PSEN2, TSPAN5, ACE, WFS1, DHCR24, CTSS, CTSG, MME, TSPAN33]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, CCR6, ATP1B1, LAT2, BTK, CXCR5, CXCR4, FPR2, CXCR1, CXCR2, AZU1, SELE, LAT]
GO:0071219;cellular response to molecule of bacterial origin;5.0;0.7980440201809971;0.6892630219514189;9.253830803050711;59.34640842185874;4.720827822332161;0.001986270881579593;0.5316643662359317;[EDNRB, GHSR, MEF2C, CD180, ADAM9, CD274, STAP1, NLRP3, FZD5, DEFA4, DEFA1, HMGB2, CXCL1, TREM2, CXCL2, CTSG, ARG1, PDCD1LG2, TLR1, CEBPE, NR1H2, FCGR2B]
GO:0060672;epithelial cell morphogenesis involved in placental branching;7.0;1.0;0.8509193652572005;9.628524252492122;83.24866829651714;8.67846133901236;0.002786258008947111;0.7947362817240173;[ST14, SPINT2]
GO:2000170;positive regulation of peptidyl-cysteine S-nitrosylation;9.0;1.0;0.896240625180289;9.628524252492122;445.472383047836;9.083926447120524;0.014909559761494903;0.8607930461318132;[ACE]
GO:0060670;branching involved in labyrinthine layer morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;72.98998111856169;7.57984905034425;0.002442908981319996;0.710754145523778;[SPINT1, FZD5]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[TFRC, FPR2, IGHA1, ELANE, MSR1, DENND1B, ANXA3, CEACAM1, RHOU, IGKC, CXCR1, CXCR2, SORT1, SIGLEC1, RAMP1, NCF4, HP, CXCL16, AP2M1, TSC2, PRTN3, CALCRL, CORO1A, IGLV1-44, MARCH3, IGKV3-20, LRP12, LRRK2, DNM2, COLEC12, NLGN1, LRP1, CEBPE, NLGN4Y, CD9, FCGR2B]
GO:0060675;ureteric bud morphogenesis;9.0;1.0;0.896240625180289;9.628524252492122;52.20233752390303;8.67846133901236;0.0017471652578714015;0.8400575416471059;[TACSTD2]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[TFRC, HP, CXCL16, AP2M1, CALCRL, FPR2, IGLV1-44, IGHA1, MSR1, IGKV3-20, LRP12, DNM2, CEACAM1, COLEC12, LRP1, IGKC, CXCR1, CXCR2, CD9, FCGR2B, RAMP1]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[TGFA, F5]
GO:0006654;phosphatidic acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;659.6112576846374;6.139487467954083;0.022076595183113425;0.6889736746265369;[AGPAT3]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, NRBP1, TGFA, SPTAN1, TMED6, F5]
GO:0046034;ATP metabolic process;10.0;0.6519675769143192;0.7412248003180799;9.106334870075816;1262.3387643731025;4.99795013456894;0.04224934241243719;0.6708364141712261;[HK3, ATP1B1, MSH2, FIGNL1, TGFB1]
GO:0071329;cellular response to sucrose stimulus;7.0;1.0;0.8509193652572005;9.628524252492122;186.89669107147486;9.777073627680469;0.006255264054060515;0.8509193652572005;[CALCRL]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[CDH1, ATP1B1, TSPAN33, FLNA, TSPAN5, JUP, RAMP1]
GO:0061551;trigeminal ganglion development;6.0;1.0;0.8231203125901445;9.628524252492122;32.51846529594618;8.390779266560578;0.0010883637687365787;0.7522251544931926;[NRP1]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[LYN, TGFB1, GSN, CD9]
GO:0015695;organic cation transport;6.0;0.6260725219892441;0.6361565735847665;8.077926840080956;30.14448825076878;6.063501560976162;0.0010089088934751224;0.6332080644001243;[SLC22A4, ABCB4, SLC7A8]
GO:0061314;Notch signaling involved in heart development;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;57.16383262977075;7.57984905034425;0.0019132220340090946;0.738553198190834;[JAG1]
GO:0090191;negative regulation of branching involved in ureteric bud morphogenesis;8.0;0.8933024483968273;0.8216512241984136;9.577230958104572;298.2680508904603;8.390779266560578;0.009982763239485454;0.8041048419030481;[TACSTD2]
GO:1904835;dorsal root ganglion morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;28.42528359967652;9.777073627680469;9.513686609867987E-4;0.7902410118609202;[NRP1]
GO:0006855;drug transmembrane transport;5.0;0.5781283279524737;0.5793051758371571;7.293149336675085;29.084245973375534;5.407625775213448;9.73423538606871E-4;0.5667872454856517;[ABCB4, SLC1A3, SLC7A11, SLC19A2, ABCC3, ABCA8]
GO:0002019;regulation of renal output by angiotensin;9.0;0.8653626801206646;0.8289219652406215;9.474373572664863;27.46031048587314;8.67846133901236;9.190718792872195E-4;0.8400575416471059;[ACE]
GO:2000178;negative regulation of neural precursor cell proliferation;6.0;0.7980440201809971;0.722142322680643;9.117698628726131;64.43316573945785;6.781341354126479;0.002156520071215264;0.6699184248047958;[TGFB1, SPINT1, SPINT2]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, TCL1A, AKT1, CHI3L1, CD58]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, TFRC, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, HHLA2, FPR1, FPR3, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, FZD5, DENND1B, SIGLEC9, ARG1, FCRL3, PAWR, PAX5, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, NR1H2, PKN1, CLC, LGR4, IGHG1, GRAP2, IL13RA2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM2, TREM1, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR2A, FCGR2B, LGALS3, ICOSLG, BTK, STXBP2, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, SH2D1A, PTK2, CD28, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FFAR2, CTSG, MUC15, LAT2, TLR1, CEACAM1, IGHD, TLR8, TLR7, TLR5, IGKC, MLH1, IL18RAP, OSCAR, CD300C, C5AR1, STAP1, NLRP3, TGFB1, IGKV3-20, HMGB2, LTF, COLEC12, SAMHD1, CNR1, TRAT1, CD4]
GO:0019805;quinolinate biosynthetic process;8.0;1.0;0.875;9.628524252492122;691.6482702327052;8.67846133901236;0.023148845161657855;0.8188169164668168;[KMO]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, HLA-DQB1, PTAFR, HLA-DQA1, HLA-DRA]
GO:0061549;sympathetic ganglion development;5.0;1.0;0.7902410118609202;9.628524252492122;31.419853007278505;7.57984905034425;0.0010515942041217404;0.6778748447945537;[NRP1, NRP2]
GO:0060218;hematopoietic stem cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;45.53364894725875;7.379178354882098;0.0015239702526411902;0.6676125360964777;[ACE]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[AKT1, MEF2C, F2R, MSH2, C5AR1, CORO1A, WFS1, NR4A2, NRP1, LRRK2, CHL1, LRP1, GPNMB]
GO:0048469;cell maturation;3.0;0.6954798709641801;0.5458602480722345;8.242229891372231;25.22197897315013;4.886724499458715;8.441569379239579E-4;0.4480276307483924;[CDKN1A, BRCA2, ROPN1L, FBXO5, RUNX2, BTK, FZD5, NR4A2, SLC26A8, SLC26A3]
GO:0061309;cardiac neural crest cell development involved in outflow tract morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;64.99956039719679;8.67846133901236;0.0021754767906876885;0.7947362817240173;[JAG1]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[ITGAM, MYB, KMO, EGR1, FCGR2B, UBE2M]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, ATP1B1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, TGFB1, WFS1, CD24, GPR18, ATP2A3, GRM5, CCR9, CCR6, CD52, SLC24A1, SLC24A4, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, GPR157, GPR6, P2RX5, CD4, GRINA]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[HMGB2, CXCL1, CXCL2, EDNRB, CTSG, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, ADAM9, CD274, CEBPE, STAP1, NLRP3, NR1H2, DEFA4, DEFA1]
GO:0006509;membrane protein ectodomain proteolysis;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;50.748517158788495;6.781341354126479;0.0016985071986044009;0.6977174774718518;[PSEN2, ADAM9, PRTN3]
GO:0071223;cellular response to lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;155.87545856417063;7.474488534686424;0.005217011319337755;0.7053660038532718;[TREM2]
GO:0072674;multinuclear osteoclast differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;47.07409398820286;9.083926447120524;0.0015755275618510598;0.8154717862087246;[TNFRSF11A]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, IGHA1, LYN, SH2D1A, PTK2, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, LILRA5, IGKC, LGR4, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, PTX3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, PDGFC, TGFB1, NOX4, NRP1, TREM2, CHI3L1, GNAI2, GPNMB, CD4]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, ELANE, BARD1, ST14, ACE, AZU1, OLR1, MMP12, FAM105A, ADAM28, APEH, IGHG1, RUVBL1, ADAM2, ADAM9, IGLV1-44, CLCA4, WFS1, DHCR24, ADAMTS20, RNF24, ANPEP, SKP2, CTSS, CTSG, MME, IGKC, RANBP1, ADAM12, PRTN3, PSEN2, TRHDE, NLRP3, TGFB1, IGKV3-20, MMP8, MMP9, LTF]
GO:0048596;embryonic camera-type eye morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;49.04309196241917;7.292166977892469;0.0016414281520649497;0.7238411236270654;[FZD5]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[KMO, CHI3L1]
GO:0071224;cellular response to peptidoglycan;6.0;1.0;0.8231203125901445;9.628524252492122;318.29655603595194;8.16763571524637;0.010653099282220678;0.7408135829017477;[NLRP3, TREM2]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[EGR1, IL1R1, IL1R2]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[KIF16B, STXBP2, CD58, GSN, ZYX]
GO:0036016;cellular response to interleukin-3;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;8.16763571524637;0.0027327542132076126;0.7408135829017477;[CSF2RB]
GO:0043507;positive regulation of JUN kinase activity;13.0;0.8653626801206646;0.8952363048279688;9.582714716460828;4931.413721535565;5.459585514144159;0.16504997927558432;0.7417584218576596;[MAP4K1, TNFRSF11A, FZD5, PKN1]
GO:0045807;positive regulation of endocytosis;7.0;0.6873818243518346;0.6946102774331178;8.89763674394933;124.48668476360231;4.886724499458715;0.0041664573082951335;0.6008266834154484;[LRRK2, SIRPB1, ACTN4, DNM2, NLGN1, CD151, LRP1, STAP1, AZU1, SELE, PTX3, FCGR2B]
GO:0038156;interleukin-3-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CSF2RB]
GO:0060086;circadian temperature homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;27.937234557965837;9.083926447120524;9.350340987763633E-4;0.7876727335416686;[TNFRSF11A]
GO:1902033;regulation of hematopoietic stem cell proliferation;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;57.23280282053753;7.9853141584524145;0.001915530404224917;0.7314896500084853;[ACE]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, TFRC, AKT1, LYN, MMP12, CSE1L, AP2M1, ACAP1, SLC27A2, LIN7A, ITGB6, LRP1, ACTN4, MSR1, EGR2, POLA2, CD24, CD3G, STX11, RAMP1, NUP155, NASP, NUP62, NUP133, TBC1D9, CHI3L1, NUP54, NUP35, RAN, NUP85, NUP88, DENND1B, LAMP2, RAB32, CALCRL, BCL6, CCDC22, NLGN1, UNC93B1, NLRC4, STXBP2, XPO1, TMED6, RANBP1, NUPL2, TSC2, ATP1B1, HGS, SUCNR1, NLRP3, TGFB1, DNM2]
GO:0051491;positive regulation of filopodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;6.409777797693995;0.006704083591926775;0.7240369598395108;[NRP1, NLGN1]
GO:0002084;protein depalmitoylation;8.0;1.0;0.875;9.628524252492122;372.9036028239795;7.57984905034425;0.012480747995064495;0.7626338329336335;[ABHD12]
GO:0097490;sympathetic neuron projection extension;5.0;1.0;0.7902410118609202;9.628524252492122;51.99108915072818;8.390779266560578;0.0017400949649324319;0.7193458537639684;[NRP1, NRP2]
GO:0007413;axonal fasciculation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;31.514364772604104;6.7325511899570465;0.0010547574278521217;0.6952223462072524;[NRP1, CNR1, NCAM2, EPHA3]
GO:0072070;loop of Henle development;8.0;0.9326813400603323;0.8413406700301662;9.533214072687796;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[JAG1]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, NRP1, CPNE5, CXCL16, AKT1, S100A8, HBEGF, SFN]
GO:0010818;T cell chemotaxis;8.0;0.8436909121759173;0.7968454560879586;9.446202695698167;127.60944988880927;7.292166977892469;0.004270973446729658;0.747921758369865;[DEFA1, CXCL16]
GO:0051482;positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;292.0931097099921;6.139487467954083;0.009776093515261451;0.7620939872166814;[F2R, C3AR1, GPR18, GPR157]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[NRP1, STMN1, LINGO1, PTK2, NR4A2, LRFN4, OGN]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, TLR8, TLR7, FZD5, CD2]
GO:0030301;cholesterol transport;7.0;0.7763722522362496;0.7391054913753253;8.999915593069748;37.84975072563126;5.845247994956144;0.0012667970942227542;0.6498456195510879;[MSR1]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, LAG3, DNM2, HLA-DQB1, HLA-DMA, RACGAP1, HLA-DQA1, HLA-DRA, FCGR2B]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, GPNMB, GHSR, BPI, GPR18]
GO:0021828;gonadotrophin-releasing hormone neuronal migration to the hypothalamus;11.0;1.0;0.9324289523296623;9.628524252492122;88.9737192139704;9.083926447120524;0.002977870310942956;0.8969813732811862;[NRP1]
GO:1902285;semaphorin-plexin signaling pathway involved in neuron projection guidance;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;27.888769134324136;7.212124270218933;9.334120046631251E-4;0.7197477358342742;[NRP1, NRP2]
GO:2001186;negative regulation of CD8-positive, alpha-beta T cell activation;10.0;0.8933024483968273;0.861892236059334;9.551563211355994;305.21353058757757;8.16763571524637;0.010215222194422061;0.8329342821725234;[CD274]
GO:2001181;positive regulation of interleukin-10 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;8.390779266560578;0.02521906460756386;0.8443458537639685;[CD274]
GO:1903375;facioacoustic ganglion development;6.0;1.0;0.8231203125901445;9.628524252492122;32.51846529594618;9.083926447120524;0.0010883637687365787;0.7876727335416686;[NRP1]
GO:1902287;semaphorin-plexin signaling pathway involved in axon guidance;8.0;1.0;0.875;9.628524252492122;28.581916314885376;7.292166977892469;9.566110170045473E-4;0.747921758369865;[NRP1]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CD3G, CD3E, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, NLRC4, SAMHD1, RAD51]
GO:1904469;positive regulation of tumor necrosis factor secretion;10.0;1.0;0.9152410118609203;9.628524252492122;775.9675723657698;7.292166977892469;0.025970936321606315;0.7881627702307852;[ORM1, FZD5, LRRK2]
GO:0086009;membrane repolarization;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;39.57817623486923;6.781341354126479;0.0013246459405349812;0.6699184248047958;[ATP1B2, ATP1B1]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[HP, SLC8A1, IL18RAP, MYB, DUSP1, ARG1, ADAM9, PCNA, FOXO1, EZH2]
GO:0032713;negative regulation of interleukin-4 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.96654663153603;7.9853141584524145;0.002174371849661483;0.7314896500084853;[CD83]
GO:0006569;tryptophan catabolic process;9.0;0.8436909121759173;0.8180860812682478;9.539576766475626;1971.8984750997497;7.474488534686424;0.06599766736817739;0.7784863164434164;[KMO]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[STMN1, TACSTD2, PFN1, ARHGAP6]
GO:0007416;synapse assembly;4.0;0.8436909121759173;0.6718454560879586;9.117698628726131;35.85243951974866;5.500407508664414;0.0011999488856252476;0.5312910957882058;[NLGN1, FZD5, PCDHB14, CDH1, PCDHB16, PCDHB4]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[NRP1, ARHGEF10L, CTGF, NOX4]
GO:0030890;positive regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.1565706318756;6.063501560976162;0.016940604907709607;0.706328376990269;[CDKN1A, TFRC, MEF2C, FCRL3, MSH6, BST1, BCL6]
GO:0016485;protein processing;6.0;0.6519675769143192;0.6491041010473041;8.320191432841943;99.81063536400724;4.720827822332161;0.0033405721418933456;0.564543666965156;[CTSS, CTSG, MME, PSEN2, ACE, DHCR24]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[CALCRL, LRP1, TFRC, CXCR1, CXCR2, AP2M1, DNM2, CEACAM1, CD9, RAMP1]
GO:0014047;glutamate secretion;10.0;0.9326813400603323;0.8815816818910864;9.574457031221845;161.52301102016722;6.8867018697843045;0.005406029817572731;0.7674272657460779;[SLC1A3]
GO:1903146;regulation of autophagy of mitochondrion;7.0;0.7369933605727446;0.7194160455435727;9.280217558223907;66.7923696051344;6.088194173566533;0.0022354805014538253;0.6622698984233759;[FZD5, TSC2]
GO:0051271;negative regulation of cellular component movement;5.0;0.5470854108181258;0.5637837172699831;7.364160372318274;52.38761662992485;4.128099389519264;0.001753366382809582;0.5013522066171892;[SPINT2, DACH1, MEF2C, ACTN1, ACTN4, PADI2, KCNE3, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, NRP1, PTPRR, MCTP1, PTPRK, ARAP3, ENG, LRP1, CD9]
GO:0006660;phosphatidylserine catabolic process;8.0;1.0;0.875;9.628524252492122;837.3304422023242;9.777073627680469;0.028024696352038317;0.875;[ABHD12]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, FZD5, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, FOXO1, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, EBF1, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, ARID4A, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, MEIS2]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, LRP1, C5AR1, CORO1A, WFS1, NR4A2]
GO:0007628;adult walking behavior;4.0;1.0;0.75;9.628524252492122;34.938319875750295;6.518977089658987;0.0011693541237948906;0.5833807915285978;[ABHD12, SCN1A]
GO:0006537;glutamate biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.593432932680852;829.4659717023219;8.16763571524637;0.027761479601967176;0.8329342821725234;[SLC1A3]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, GHSR, DUSP1, ANXA3, ARG1, ADAM9, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL]
GO:1903278;positive regulation of sodium ion export across plasma membrane;10.0;1.0;0.9152410118609203;9.628524252492122;363.3657930958667;8.390779266560578;0.012161526086936028;0.8443458537639685;[ATP1B2, ATP1B1]
GO:0045830;positive regulation of isotype switching;10.0;0.8259837884571596;0.8282329060895002;9.562926970006309;1202.2270179172035;6.686031174322154;0.04023745635561778;0.7571649570480019;[TGFB1, TFRC, MLH1, UNG, MSH6, MSH2, CD28]
GO:0044861;protein transport into plasma membrane raft;11.0;1.0;0.9324289523296623;9.628524252492122;279.98422179103943;9.083926447120524;0.009370819933905719;0.8969813732811862;[ATP1B1]
GO:0035094;response to nicotine;4.0;0.9326813400603323;0.7163406700301662;9.446202695698167;26.17342148764107;5.926926025970411;8.760008626412986E-4;0.5531032725983739;[CHRNB4, SLC7A11, CNR1]
GO:0042447;hormone catabolic process;5.0;0.657518819034173;0.6190004213780067;8.048073876931273;28.890480996358985;7.138016298065211;9.669383992032849E-4;0.6552794972956795;[ACE]
GO:0097352;autophagosome maturation;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.599019797332524;0.0012734203321220245;0.6277151911823093;[LAMP2]
GO:0097475;motor neuron migration;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;22.707504301080803;7.8311634786251565;7.599997335300838E-4;0.7236063770733796;[NRP1]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[SLA2, FGF5, GRAP2, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, LYN, BMX, PTK2, HBEGF, WEE1]
GO:1902475;L-alpha-amino acid transmembrane transport;10.0;0.6181399273706679;0.7243109755462542;8.529911963824013;268.42115299878213;6.063501560976162;0.00898381442751516;0.7253287636709003;[SLC1A3, SLC7A11, SLC7A8]
GO:1902476;chloride transmembrane transport;8.0;1.0;0.875;9.628524252492122;110.5175749436453;5.311165509025885;0.0036989237740038075;0.6466132511260384;[SLC1A3, GABRE, CLCA4, CLDN4, SLC26A8, CLDN17, SLC26A3]
GO:1902236;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;830.7594506111926;6.832634648514029;0.02780477117699164;0.7646622655359331;[WFS1, LRRK2, GRINA]
GO:0009756;carbohydrate mediated signaling;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;23.17027026302992;8.390779266560578;7.75488093814194E-4;0.7193458537639684;[COLEC12]
GO:0006488;dolichol-linked oligosaccharide biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;80.91159753301743;7.069023426578259;0.00270803835371991;0.6846304993685643;[SRD5A3]
GO:0006489;dolichyl diphosphate biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;346.04394917679554;8.16763571524637;0.011581779559612143;0.7686126355688037;[SRD5A3]
GO:0052651;monoacylglycerol catabolic process;8.0;1.0;0.875;9.628524252492122;491.79843549514675;9.083926447120524;0.016460051046165984;0.839552420951524;[ABHD12]
GO:0060050;positive regulation of protein glycosylation;9.0;0.8933024483968273;0.8428918493787028;9.569683752469189;1332.0695725107485;7.57984905034425;0.04458316980715119;0.7838744581139225;[RAMP1]
GO:0042987;amyloid precursor protein catabolic process;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;48.551292581453126;7.57984905034425;0.0016249680693747237;0.710754145523778;[PSEN2, DHCR24]
GO:0007220;Notch receptor processing;6.0;1.0;0.8231203125901445;9.628524252492122;83.35257022185557;7.379178354882098;0.0027897355128825266;0.7004918368257019;[PSEN2]
GO:0007223;Wnt signaling pathway, calcium modulating pathway;9.0;1.0;0.896240625180289;9.628524252492122;33.206889128170424;6.250713103064308;0.001111404694859899;0.7159023839588838;[FZD5]
GO:1905516;positive regulation of fertilization;5.0;0.8653626801206646;0.7229223519212526;9.427853557029971;78.82632625976231;7.292166977892469;0.0026382462008263663;0.6631627702307852;[LHFPL2]
GO:0007342;fusion of sperm to egg plasma membrane involved in single fertilization;6.0;1.0;0.8231203125901445;9.628524252492122;41.84633322739465;7.004484905440688;0.0014005591138660403;0.6813299963962409;[ADAM2, CD9, FOLR3]
GO:0030216;keratinocyte differentiation;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;25.58801435984686;5.486614186532078;8.564078129062366E-4;0.6037060172430475;[ST14, JAG1, ADAM9]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2C, ATF3, IQGAP3, PKIG, EZH2, MMP12, FLNA, LGR4, GMNN, CTGF, FOXO1, CIITA, LRRK2, HHEX, E2F7, PCBP3, EGR1, MSR1, CD28, PTPRK, CD3E, BANK1, CCNE1, HMGA1, MXD1, HMGB2, FBP1, MYB, ELANE, BARD1, NDFIP2, CDKN1A, PAWR, PAX5, AES, ENG, NR1H2, DACH1, TLE4, MAP2K2, NACC2, WFS1, BCL6, CNOT3, CR1, RFC1, NLRC4, RBBP8, KLF8, KLF5, ZNF608, EDNRB, PPP2R1A, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, BASP1, TGFB1, CBX4, NR4A2, MEIS2]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[HHEX, FCER2, PSEN2, TGFB1, JAG1, KRT19]
GO:0072015;glomerular visceral epithelial cell development;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;35.73672554677016;7.474488534686424;0.0011960760430854717;0.7053660038532718;[JAG1]
GO:0050482;arachidonic acid secretion;12.0;1.0;0.9481203125901445;9.628524252492122;224.85573033724626;6.599019797332524;0.007525718937368459;0.7855944919115336;[ACE]
GO:0072017;distal tubule development;8.0;0.8653626801206646;0.8076813400603323;9.36615998802463;58.05347923817328;8.390779266560578;0.001942997705362361;0.8041048419030481;[JAG1]
GO:0032870;cellular response to hormone stimulus;5.0;0.6039883530135606;0.5922351883677006;7.932074963068391;80.94247679971589;3.9540277321974506;0.0027090718549867714;0.49245017396659174;[CYFIP1, PID1, AKT1, GHSR, LHCGR, MEF2C, POR, ADCY9, SIK1, ABCB4, FOXO1, PRKAR2B, IGFBP7, GAS2L1, TGFB1, CDC6, INHBA, NR4A2, NR4A1, CTSS, DUSP1, ARG1, GLP2R, CEACAM1, P2RY6, TSHR, RAMP1]
GO:0001916;positive regulation of T cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.523163736834295;365.14378084230765;6.518977089658987;0.012221033736724321;0.7296214167088868;[CD1E, CD1B, CD1A]
GO:0010744;positive regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;113.85781812010546;7.004484905440688;0.0038107187070962377;0.6813299963962409;[MSR1]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[DACH1, MEF2C, PADI2, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, PTPRR, MCTP1, PTPRK, ARAP3, ENG, LRP1]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, PDGFC, ELANE, LYN, PLK2, PTK2, NOX4, NRP1, NRP2, CCR6, ANXA3, GAB1, CEACAM6, HBEGF, PTAFR, PTGS2, GNAI2, GPNMB, CXCR2, FLNA, SLC8A1, CXCL16, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, DOCK5, TNFAIP6, LAMC2, CXCL1, CXCL2, MMP9, P2RY6]
GO:1901166;neural crest cell migration involved in autonomic nervous system development;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;23.960267269578353;8.390779266560578;8.01928582672223E-4;0.7800242071602487;[NRP1]
GO:1902378;VEGF-activated neuropilin signaling pathway involved in axon guidance;10.0;1.0;0.9152410118609203;9.628524252492122;58.60337150540505;9.777073627680469;0.0019614021046756975;0.9152410118609203;[NRP1]
GO:1905404;positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process;11.0;1.0;0.9324289523296623;9.628524252492122;182.59973364650156;9.777073627680469;0.0061114487560572734;0.9324289523296623;[CD274]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[SPINT2, AKT1, POR, SPINT1, SLPI, SFN, TNFRSF10C, CRIM1, DHCR24, CR1, MMP9, LTF, SERPINB10, NLRC4, PTGS2]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, NR4A2, LGR4]
GO:0030321;transepithelial chloride transport;8.0;1.0;0.875;9.628524252492122;29.941547406775403;8.16763571524637;0.001002116646061566;0.7926932703116032;[P2RY6]
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;9.0;0.7436939687323844;0.7680876095464813;9.094441766561864;99.0414819593438;5.825829909099042;0.0033148292696323837;0.694173837660411;[CELSR1, AP2M1, FZD5, VANGL1, PFN1]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, FLNA, CXADR, GAB1]
GO:0032743;positive regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.409777797693995;0.002183412136085803;0.6509166472493662;[CD83, CD3E, CD4, CD28]
GO:0060177;regulation of angiotensin metabolic process;6.0;1.0;0.8231203125901445;9.628524252492122;43.97722126997476;9.083926447120524;0.001471878018976464;0.7876727335416686;[SUCNR1, ACE]
GO:0019408;dolichol biosynthetic process;8.0;1.0;0.875;9.628524252492122;352.4236781976971;9.083926447120524;0.011795303348558361;0.839552420951524;[SRD5A3]
GO:1903597;negative regulation of gap junction assembly;7.0;1.0;0.8509193652572005;9.628524252492122;107.40702245958384;9.777073627680469;0.003594816381677759;0.8509193652572005;[ACE]
GO:0038043;interleukin-5-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CSF2RB]
GO:1900086;positive regulation of peptidyl-tyrosine autophosphorylation;11.0;1.0;0.9324289523296623;9.628524252492122;1786.9389585583017;8.16763571524637;0.05980723880229299;0.8501222226412654;[ACE]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[LHCGR, C5AR1, F2R, FPR1, FPR3, FPR2, GPR84, GRM5, P2RY6, EDNRB, CXCR2, C3AR1]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CD24, GPR18, CCR9, CCR6, CD52, CXCR5, CXCR4, CXCR1, CXCR2, GPR157, GPR6, P2RX5, CD4]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[PID1, EHMT2, SLA2, SPIB, AKT1, MEF2C, ATF3, JAG1, JUP, PKIG, EZH2, MMP12, PTAFR, ZNF467, ATAD2, PKN1, RUVBL1, MAZ, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, TGFA, PCBP3, EGR1, EGR2, EGR3, CD28, NR3C2, CCNE1, HMGA1, INHBA, TCF4, MXD1, HMGB2, ARHGEF10L, FBP1, CREB5, EHF, HOXA9, MYB, ELANE, NFE2, FZD5, CDKN1A, ZNF367, BRD2, PAWR, PAX5, AES, ENG, EPCAM, NR1H2, GTF2H1, DACH1, TLE4, NACC2, WFS1, BCL6, MAFF, RFC1, CEBPE, RBBP8, KLF8, KLF5, PPIL4, ZNF608, EDNRB, CHEK1, EBF1, RUNX2, PFN1, BEX1, BCL11B, BCL11A, PRL, XPO1, ARID4A, NLRP3, TGFB1, CBX4, NR4A2, NR4A1, SLC40A1, CKAP2, MEIS2]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[TGFB1, TFRC, TREM2, TNFRSF11A, OSCAR]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCR4, CXCL1, CXCL2, CXCR1, CXCR2, CCRL2, CCR9, CCR6]
GO:0016264;gap junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;7.8311634786251565;0.001878987018571015;0.7236063770733796;[GJC1, GJB2]
GO:0016024;CDP-diacylglycerol biosynthetic process;8.0;1.0;0.875;9.628524252492122;660.3044048651973;7.212124270218933;0.0220997941954548;0.7438283705770736;[AGPAT3]
GO:0032733;positive regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.375876246018314;0.002183412136085803;0.6491829203200885;[CD274, CD83, CD28]
GO:0032693;negative regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.943860283624253;0.002184000309729388;0.6782296504172152;[CD274, PRG2, PDCD1LG2, FCGR2B]
GO:0022408;negative regulation of cell-cell adhesion;6.0;0.5806842727486619;0.6134624489644754;7.765305819281922;52.92767189200162;4.7081694254602375;0.0017714415464131104;0.5638963159604501;[, IFNA2, SPINT2, LGALS3, CDH1, TNR, LAG3, ARG1, PAWR, PDCD1LG2, CEACAM1, CD274, GPNMB, EPCAM, TGFB1, JAG1, PTK2, BCL6, CD9, FCGR2B]
GO:0090331;negative regulation of platelet aggregation;10.0;0.9326813400603323;0.8815816818910864;9.601125278304007;548.6740902153413;7.379178354882098;0.01836362802488484;0.7926125360964777;[CEACAM1, CD9]
GO:1905146;lysosomal protein catabolic process;8.0;1.0;0.875;9.628524252492122;325.4145966205827;8.67846133901236;0.010891333694767644;0.8188169164668168;[LAMP2]
GO:0009435;NAD biosynthetic process;11.0;0.7980440201809971;0.8314509624201607;9.500690880982237;2002.0309936558642;5.825829909099042;0.06700617564674446;0.730362164809784;[PTGS2, HK3, KMO]
GO:0045765;regulation of angiogenesis;6.0;0.7043150770688792;0.675277851124584;8.817594036275793;44.93985318205118;4.1639455212923995;0.0015040964427611868;0.5360646801923071;[CDH5, C3AR1, PROK2, GHSR, HGS, ADAM12, C5AR1, JUP, PLK2, NRP1, PRL, HHEX, ANXA3, GAB1, CEACAM1, CHI3L1, ENG, PTGS2, GPNMB, CXCR2, LRG1]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[BTK, S100A8, TNFRSF11A, NLRP3, TGFB1, LTF, NLRC4]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA3, GAB1, ADAM12, CHI3L1, ENG, C5AR1, PTGS2, CXCR2, JUP, PLK2, LRG1]
GO:0051088;PMA-inducible membrane protein ectodomain proteolysis;8.0;1.0;0.875;9.628524252492122;51.441664339349536;8.67846133901236;0.0017217062109458165;0.8188169164668168;[ADAM9]
GO:0016095;polyprenol catabolic process;7.0;0.8933024483968273;0.7975705894556142;9.541512875502493;320.2501318467851;8.67846133901236;0.01071848370650518;0.7947362817240173;[SRD5A3]
GO:1990408;calcitonin gene-related peptide receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;28.075545041466096;9.083926447120524;9.396632261877633E-4;0.8154717862087246;[CALCRL, RAMP1]
GO:0032689;negative regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.343086423195323;0.002184000309729388;0.647506047256038;[CD274, INHBA, PDCD1LG2]
GO:1903082;positive regulation of C-C chemokine receptor CCR7 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;365.88844033500624;9.777073627680469;0.01224595681979491;0.896240625180289;[TREM2]
GO:0071812;positive regulation of fever generation by positive regulation of prostaglandin secretion;11.0;1.0;0.9324289523296623;9.628524252492122;762.7474768735852;9.083926447120524;0.025528471622796402;0.8969813732811862;[TNFRSF11A]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK5, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNJ15, KCNJ16, ATP1B2, ATP1B1]
GO:0008595;anterior/posterior axis specification, embryo;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;40.32465619079058;7.697632086000634;0.0013496299528713244;0.6838982747154925;[FZD5]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[GRM5, CHRNB4, NPY1R, SLC1A3, GJC1, SV2A, HRH4, KCNMB3, GABRE, EGR3, HTR1E, PCDHB14, PNOC, PCDHB16, PCDHB4, GPR19]
GO:0009449;gamma-aminobutyric acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;747.1446474653511;8.67846133901236;0.025006258964137613;0.8188169164668168;[SLC1A3]
GO:1990410;adrenomedullin receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;55.74562497482455;8.390779266560578;0.0018657559001020701;0.7800242071602487;[CALCRL]
GO:0001953;negative regulation of cell-matrix adhesion;7.0;0.8653626801206646;0.7836007053175329;9.387362195675234;66.9585131603638;6.280566066213989;0.002241041176727861;0.6721078059595746;[JAG1, ARHGAP6, BCL6]
GO:0045780;positive regulation of bone resorption;7.0;1.0;0.8509193652572005;9.628524252492122;82.90338698468558;6.943860283624253;0.002774701754173115;0.7060287030842711;[TFRC, TNFRSF11A]
GO:0031581;hemidesmosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;36.796901128588246;7.292166977892469;0.0012315591657128446;0.6960420709600095;[CD151, LAMB3, ITGB4, LAMA3, LAMC2]
GO:0006024;glycosaminoglycan biosynthetic process;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;237.49504005673018;5.16195311083921;0.007948745259039342;0.5871028347338303;[SDC2, NDST3, ST3GAL6, OGN]
GO:0045665;negative regulation of neuron differentiation;8.0;0.6162540371078848;0.6831270185539424;8.732436227935485;338.1488864638422;4.401795219996305;0.011317538915704735;0.6001080122550225;[EDNRB, TNR, JAG1, PLK2, PTK2, ITM2C, NRP1, LRRK2, NLGN1, LRP1, LINGO1]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[MSH6, MELK, MSH2, LGALS12, BTK, LY96, TNFRSF11A, SFN, TGFB1, TNFRSF10C, INHBA, CD28, CD24, CDKN1A, BRCA2, CD3E, PAWR, SORT1, G0S2, MLH1]
GO:0044332;Wnt signaling pathway involved in dorsal/ventral axis specification;8.0;1.0;0.875;9.628524252492122;31.415129658942366;7.9853141584524145;0.0010514361179036673;0.7833693374183408;[FZD5]
GO:0045669;positive regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;169.86351353303945;5.734022359845919;0.005685178930713632;0.6163584827319739;[MEF2C, JAG1, RUNX2, LTF]
GO:0048814;regulation of dendrite morphogenesis;10.0;0.8259837884571596;0.8282329060895002;9.533214072687796;153.5143611256957;5.334422371190153;0.0051379875129217364;0.6880436199995941;[NLGN1, LRRK2, SDC2]
GO:0006027;glycosaminoglycan catabolic process;6.0;0.7866048967936545;0.7164227609869718;9.245532000236016;234.16675596998346;5.618190544320798;0.00783735058591714;0.610434838299289;[SDC2, TGFB1, OGN]
GO:0048813;dendrite morphogenesis;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;64.60914726719044;6.063501560976162;0.0021624100145753813;0.6850877518099798;[NRP1, SDC2]
GO:0009414;response to water deprivation;5.0;0.8436909121759173;0.712086467948879;9.427853557029971;59.73918226934355;7.697632086000634;0.001999416668781396;0.6838982747154925;[CD9, SIPA1, LRP11]
GO:0030007;cellular potassium ion homeostasis;9.0;0.9326813400603323;0.8625812952104552;9.574457031221845;285.76071857591336;7.138016298065211;0.009564154082785858;0.7612791106150483;[ATP1B2, ATP1B1]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[NRP1, ITGAM, ITGB4, CTGF, ITGB6, CEACAM1, ADAM9, TLN1, PTK2, ZYX, LAT]
GO:0043372;positive regulation of CD4-positive, alpha-beta T cell differentiation;11.0;0.7980440201809971;0.8314509624201607;9.541512875502493;1782.7320683291834;6.409777797693995;0.0596664379722798;0.7602252869888839;[CD83, MYB, NLRP3]
GO:0060828;regulation of canonical Wnt signaling pathway;7.0;0.6954798709641801;0.6986593007392905;8.83001655627435;44.04846258837617;4.37439624580819;0.0014742624017903352;0.5746261926980603;[RUVBL1, TLE4, FOXO1, EGR1, JUP, FZD5, CDK14, LRRK2, AES, PPP1CA, SULF2, LGR4]
GO:0043252;sodium-independent organic anion transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.887457555831563;6.444869117505266;0.0010672445075450394;0.6805102716434839;[SLCO2B1, SLCO4C1]
GO:0010633;negative regulation of epithelial cell migration;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;243.45111910585655;5.602686357784832;0.008148089864690466;0.6615216408886768;[PTPRR, TACSTD2, MEF2C, TGFB1, JUP]
GO:0033630;positive regulation of cell adhesion mediated by integrin;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.61675044652454;6.943860283624253;0.0011585914843924019;0.6453503496879909;[ADAM9]
GO:2000810;regulation of bicellular tight junction assembly;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;28.92769022108224;6.781341354126479;9.681837584686441E-4;0.6699184248047958;[FZD5, GPBAR1]
GO:0086064;cell communication by electrical coupling involved in cardiac conduction;4.0;0.8259837884571596;0.6629918942285797;8.935377071932177;22.009319849728328;7.138016298065211;7.366321282685284E-4;0.6150384854347593;[GJC1, ATP1B2, ATP1B1, SLC8A1]
GO:0019229;regulation of vasoconstriction;7.0;0.7369933605727446;0.7194160455435727;9.310070521373587;55.827436365827396;5.500407508664414;0.0018684940537334635;0.6322104610454062;[DOCK5, PTAFR, PTGS2, AKT1, ACE, F2R]
GO:0032781;positive regulation of ATPase activity;6.0;0.7508913569872202;0.6985659910837546;8.781226392104918;51.416896668601964;5.8067817141283475;0.0017208772592953517;0.6200793994936333;[ATP1B2, ATP1B1, DNM2, PFN1]
GO:0038084;vascular endothelial growth factor signaling pathway;8.0;0.7763722522362496;0.7631861261181248;9.117698628726131;31.002284443533863;6.781341354126479;0.0010376185600805164;0.7217981122146513;[NRP1, NRP2, GAB1]
GO:0010886;positive regulation of cholesterol storage;7.0;1.0;0.8509193652572005;9.628524252492122;69.4460343959197;7.8311634786251565;0.002324296273858149;0.7514054297404357;[MSR1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, CXCL16, VPREB3, LGALS3, VPREB1, EDNRB, C3AR1, CD177, CXADR, ATP1B2, ATP1B1, PRTN3, S100A8, GYPA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, TGFB1, GPR15, AZU1, DEFA1, SELE, IGKV3-20, IGHM, ITGAM, CXCL1, SLC7A11, CXCL2, TREM1, OLR1, FFAR2, CCR6, MMP9, CEACAM1, SLC7A8, CEACAM6, CXCR5, CXCR4, IGKC, CXCR1, EPCAM, CXCR2, CD58, JAM2, JAM3, CD2, NLRP12]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[NRP1, NRP2, HMGB2, AKT1, GHSR, EGR3, ARG1, NR4A1, LRG1]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[NR4A1, NRP1, EGR3, AKT1]
GO:0010882;regulation of cardiac muscle contraction by calcium ion signaling;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;68.46878113000767;6.641579411751319;0.0022915884865189126;0.7358913051622797;[ATP1B1, SLC8A1]
GO:0017038;protein import;8.0;0.7436939687323844;0.7468469843661922;8.977936686350972;57.348299591639034;4.842599694549778;0.0019193959772133386;0.6226507735831915;[NUP107, CSE1L, NUP62, LAMP2, NUP133, TSC2, MMP12, NUP54, NUP85, NUP88, RANBP1, NUP155, NUP35, RAN]
GO:0032495;response to muramyl dipeptide;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.66765988983927;7.004484905440688;0.0019970228791053504;0.6813299963962409;[JAG1]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[TGFA, REPS2, AKT1, TGFB1, GAB1, PTK2, BTC, KIF16B, HBEGF]
GO:0061098;positive regulation of protein tyrosine kinase activity;11.0;0.8436909121759173;0.8542744084176208;9.55953138100517;2154.6219316186807;5.8650506222523235;0.07211325701743153;0.7323679139043926;[TGFA, GRM5, STAP1, ACE, CD24]
GO:1903288;positive regulation of potassium ion import;10.0;1.0;0.9152410118609203;9.628524252492122;414.29394802332047;8.67846133901236;0.01386604559999416;0.8590579283277371;[ATP1B2, ATP1B1]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[PTPRK, CDH5, ADAM9, TGFB1, PTK2, ZYX]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[TGFA, NUP62, SH2B1, RANBP1, TGFB1, BTC, CD28]
GO:0097052;L-kynurenine metabolic process;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;166.05137813699233;7.9853141584524145;0.0055575901897070516;0.8046099625986299;[KMO]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RACGAP1, EZH2, DENND1B, NRP1, ARHGAP6, RHOG, RANBP1, SIPA1, RGS1, F2R, TSC2, ACAP1, PRTN3, ADAP2, LRRK2, TBC1D9, ARAP3, ALDH1A1]
GO:0045602;negative regulation of endothelial cell differentiation;7.0;0.8436909121759173;0.7727648213451592;9.503361109538115;205.47603111014118;7.697632086000634;0.006877097844834217;0.7445766281117727;[JAG1]
GO:0097286;iron ion import;9.0;0.811012628672052;0.801746939516315;9.34084218004034;21.55438260674849;7.004484905440688;7.214057881629303E-4;0.7544503089863854;[STEAP4, TFRC]
GO:0051044;positive regulation of membrane protein ectodomain proteolysis;9.0;1.0;0.896240625180289;9.628524252492122;964.0127980139503;7.069023426578259;0.03226464079433516;0.757750811958709;[ADAM9]
GO:1903281;positive regulation of calcium:sodium antiporter activity;11.0;1.0;0.9324289523296623;9.628524252492122;1610.6520007917477;9.083926447120524;0.05390707297380812;0.8969813732811862;[ATP1B1]
GO:0032489;regulation of Cdc42 protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;50.14528765113853;7.8311634786251565;0.0016783176498546674;0.8157270763441555;[NRP1]
GO:1903296;positive regulation of glutamate secretion, neurotransmission;10.0;0.9326813400603323;0.8815816818910864;9.604993755081928;1142.895349618749;8.67846133901236;0.03825167881270328;0.8590579283277371;[KMO]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, TAS2R10, TRHR, ADCY9, FPR1, FPR3, FPR2, GPR15, FZD5, AZU1, PNOC, GPR18, GPR19, CD3E, CCR9, FFAR2, CCR6, RHOG, GPBAR1, TACR3, SORCS3, PTAFR, CXCR5, CXCR4, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, P2RY14, GPR6, RAMP1, LGR4, CELSR1, CXCL16, RGS1, CCRL2, GHSR, LHCGR, F2R, NPY1R, DGKZ, SUCNR1, CALCRL, C5AR1, GPR84, HRH4, HTR1E, GNB2, TAS2R7, OR1G1, CXCL1, CXCL2, GRM5, GLP2R, LRP1, P2RY6, CNR1, TSHR, OR11A1]
GO:0033572;transferrin transport;10.0;1.0;0.9152410118609203;9.628524252492122;96.80640656383476;6.193554689224359;0.0032400233075819585;0.731979686697602;[TFRC, DNM2]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MEF2C, RUNX2, JAG1, BCL11B, FZD5, INHBA, NR4A2, ITM2C]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, BPI, ACPP, FCGR2A, FOLR3, LGALS3, ANPEP, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, CTSG, SPTAN1, CAMP, MME, RHOG, CEACAM1, CEACAM6, LILRA3, CXCR1, CXCR2, CD58, QPCT, CHRNB4, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, ICOSLG, PDCD1LG2, CD274, BLM, HHLA2, CORO1A, CD4, CD28, CD24]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[CALCRL, GNAI2, LHCGR, TSHR, ADCY9, RAMP1, LGR4]
GO:0008277;regulation of G-protein coupled receptor protein signaling pathway;6.0;0.5383299095163034;0.5922852673482962;7.5335785242763205;41.8512380110395;4.8942717050940985;0.0014007232725606145;0.5734135951955668;[, LRRK2, RGS1, STMN1, ACPP, RASGRP4, GNAI2, RAMP1]
GO:1990573;potassium ion import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;262.9545538247555;7.57984905034425;0.008800852272780338;0.8200627852632958;[ATP1B1]
GO:0002845;positive regulation of tolerance induction to tumor cell;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;713.7022344563633;9.777073627680469;0.023886971496944485;0.9152410118609203;[CD274]
GO:0002726;positive regulation of T cell cytokine production;9.0;0.8933024483968273;0.8428918493787028;9.566003895510788;628.0492900660103;7.069023426578259;0.02102024453084469;0.757750811958709;[FZD5, NLRP3]
GO:0035745;T-helper 2 cell cytokine production;8.0;1.0;0.875;9.628524252492122;53.326986718937256;8.67846133901236;0.0017848062543106336;0.8188169164668168;[DENND1B]
GO:0010107;potassium ion import;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;121.72212082045542;6.063501560976162;0.004073929841064025;0.7253287636709003;[KCNJ15, KCNJ16, ATP1B2, ATP1B1]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, CXCL16, FGF5, VSTM1, MEF2C, IFNA14, IFNA16, BTC, IFNA10, TGFA, PDGFC, IFNA21, TGFB1, JAG1, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, NRP1, IFNA7, IFNA2, CXCL1, PRL, IFNA8, CXCL2, HBEGF, NLGN1, RETN, GPNMB, CMTM2, FCGR2B]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[TFRC, ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA, GPR15]
GO:0086013;membrane repolarization during cardiac muscle cell action potential;8.0;0.811012628672052;0.780506314336026;9.249034630787218;81.641259119529;7.004484905440688;0.0027324594703676576;0.7332096838060964;[ATP1B1]
GO:0046716;muscle cell cellular homeostasis;5.0;1.0;0.7902410118609202;9.628524252492122;31.94563669038233;6.781341354126479;0.0010691917108206317;0.6370391240755715;[LAMP2]
GO:0045741;positive regulation of epidermal growth factor-activated receptor activity;12.0;0.9326813400603323;0.9144609826203107;9.611429819132821;2972.107935112762;7.292166977892469;0.09947377786474029;0.8210420709600095;[TGFA]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[SKP2, ESCO2, SDC2, F5, NUCB1, IGFBP7, WFS1, CCDC22, UBE2M]
GO:0045747;positive regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;187.6437959822434;5.926926025970411;0.006280268983073171;0.6540226378555745;[TSPAN5, JAG1]
GO:0045986;negative regulation of smooth muscle contraction;8.0;0.7508913569872202;0.7504456784936101;8.98189708756707;66.40311154199819;7.138016298065211;0.002222452384390169;0.7400384854347593;[DOCK5, CALCRL, PTGS2]
GO:2000738;positive regulation of stem cell differentiation;6.0;0.7763722522362496;0.7113064387082693;9.193206181234276;114.95643040877245;6.832634648514029;0.003847488271711053;0.6725415662651573;[TACSTD2, LTBP3]
GO:0097028;dendritic cell differentiation;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;22.452520143917486;6.343086423195323;7.514656432606705E-4;0.6146267465268138;[LYN, TGFB1, TREM2, CAMK4, PRTN3]
GO:2000737;negative regulation of stem cell differentiation;6.0;0.7586651285174919;0.7024528768488905;9.136047767394327;115.31702415177813;6.781341354126479;0.0038595570197761534;0.6699184248047958;[JAG1]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[DOCK5, NRP1, P2RY6, NOX4]
GO:0014910;regulation of smooth muscle cell migration;7.0;0.7866048967936545;0.7442218136540277;9.260799472366804;40.03709713961528;5.71663061713405;0.0013400056102148314;0.6432681208679463;[DOCK5, NRP1, LRP1, P2RY6, MEF2C, ACE, NOX4]
GO:0032469;endoplasmic reticulum calcium ion homeostasis;10.0;0.8259837884571596;0.8282329060895002;9.52844079393514;288.6919123283276;6.686031174322154;0.009662258499776054;0.7571649570480019;[WFS1, GRINA]
GO:0045639;positive regulation of myeloid cell differentiation;7.0;0.7307253602413294;0.7162820453778652;9.186691500213083;278.20784311065285;5.311165509025885;0.0093113661381102;0.622532616383239;[HMGB2, JAG1, INHBA, CD4, ACIN1]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, TREM2, AKT1, RHOG, EPHA3]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, HHLA2, FPR1, FPR3, FPR2, PDGFC, LYN, JAG1, VANGL1, SIGLEC9, LRRC4, PTAFR, PTGS2, FLNA, P2RY13, P2RY14, LGR4, NCF4, F13A1, CTGF, AP2M1, LAG3, IFNA14, IFNA16, IFNA10, BLK, CD274, TACSTD2, LY96, TNFRSF11A, CORO1A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TSPAN33, TSPAN13, FCGR2A, FCGR2B, BTC, BTK, EPHA3, SDC2, TGFA, CD19, TSPAN5, TSPAN2, EGR1, PTK2, CD28, CD24, IGHM, NRP1, PTPRR, NRP2, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, CD37, CCR6, MUC15, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, CCRL2, GEM, OSCAR, CCNE1, PSEN2, RASGRP4, CRIM1, INHBA, GH1, IGKV3-20, SIRPB1, GRM5, NUP62, MMP9, SAMHD1, CD2, CD4, CD7, CD9, CDA, CYFIP1, STMN1, GPR171, IGHA1, HLA-DQA1, FZD5, CDK14, DENND1B, CDKN1A, AES, FCER2, HBEGF, ENG, HLA-DQB1, ALOX5, GPR157, G0S2, SULF2, ZYX, CSF3R, FGF5, CDH5, IGHG1, CDH3, GRAP2, IL13RA2, TLE4, CLEC4D, ADAM9, CD151, CALCRL, IGLV1-44, BCL6, LAT, CR2, CR1, P2RY6, P2RX5, EDNRB, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, CD79B, CD79A, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GPBAR1, PDCD1LG2, IL17RB, CEACAM1, RHOU, CXCR5, CXCR4, CXCR1, CXCR2, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, BLNK, GLP2R, REPS2, TRAT1, TSHR]
GO:0042491;inner ear auditory receptor cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;103.53578895689377;7.9853141584524145;0.003465249680226682;0.7592887026755414;[JAG1]
GO:0035729;cellular response to hepatocyte growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;78.10713999468214;7.138016298065211;0.00261417568375975;0.6881587980249038;[NRP1]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[CD274, GPNMB, TGFB1, ARG1, PAWR, PDCD1LG2]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A1, SLC24A4, SLC8A1, SCN1A, ATP1B2, ATP1B1, SLC6A6]
GO:0032456;endocytic recycling;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;48.979792040619635;6.409777797693995;0.0016393095606485504;0.6509166472493662;[DENND1B]
GO:0050718;positive regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;998.8167007681584;6.518977089658987;0.033429496098039586;0.7658097438582601;[ORM1, FZD5, NLRP12, TLR8, NLRP3]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[NRP1, PLK2, PTGS2]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, NR4A2, NOX4, CD24, CXCR4, PTGS2]
GO:0071773;cellular response to BMP stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.280566066213989;0.003262744749111514;0.6443087532925187;[SPINT1, SPINT2, RUNX2]
GO:0031077;post-embryonic camera-type eye development;7.0;1.0;0.8509193652572005;9.628524252492122;36.784493016758105;8.390779266560578;0.0012311438773764656;0.7800242071602487;[BCL11B, FZD5]
GO:0050714;positive regulation of protein secretion;8.0;0.6467165523344657;0.6983582761672329;8.730582659286164;381.48337166918856;4.304802954008995;0.01276790513702299;0.5951478232618299;[CLEC5A, F2R, ADAM9, BLK, CD274, NLRP3, TGFB1, FZD5, ORM1, LRRK2, FFAR2, IL17RB, MMP12, TLR1, IGHD, TLR8, CD58, NR1H2, CD2, NLRP12]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, PKN1, LGR4, CTGF, MSH6, MSH2, BLK, LY96, BMX, CORO2A, LRRK2, E2F7, SH2B1, BTC, BTK, RACGAP1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, CCR6, SPTAN1, LAT2, PCNA, GNAI2, RAMP1, CELSR1, CCRL2, DOK3, PSEN2, RASGRP4, GH1, GRM5, EPS8L1, CYFIP1, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, CIT, HBEGF, GSN, SLC8A1, FGF5, GRAP2, STK32B, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, DHCR24, BCL6, CNOT3, LAT, TREM1, EDNRB, PPP2R1A, CHEK1, SIK1, PRL, RALGPS2, MAP4K1, RHOG, TLR8, TLR7, RHOU, SGK1, CXCR5, CXCR4, CXCR1, CXCR2, MLH1, CAMK4, SIPA1, TSC2, ATP1B1, CSF2RB, TGFB1, SELE, DOCK5, MCTP1, CXCL1, BLNK, TSHR]
GO:0055065;metal ion homeostasis;7.0;0.5744162724172468;0.6381275014658239;7.901303304401638;34.207534478055855;3.4003466797818422;0.0011448953941982165;0.5248132525935356;[TFRC, EDNRB, C3AR1, PROK2, FPR1, FPR3, FPR2, CD19, ELANE, CYP4F2, CD24, GPR18, CCR9, CCR6, CD52, SLC7A8, CXCR5, CXCR4, CXCR1, CXCR2, GPR157, GPR6, GRINA, STEAP4, SLC8A1, CCRL2, F2R, ATP1B2, ATP1B1, C5AR1, HRH4, TGFB1, WFS1, LCN2, CCDC22, ATP2A3, SLC40A1, GRM5, LTF, SLC24A1, SLC24A4, SV2A, P2RX5, CD4]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, CDH5, GHSR, IL1R2, CALCRL, NLRP3, ELANE, NLRP12, FCGR2B]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[FFAR2, IL17RB, BTK, TLR10, TLR7, S100A8, SUCNR1, TNFRSF11A, PTGS2, PLA2G7, CNR1, NLRP12, CD28]
GO:1902600;proton transmembrane transport;8.0;0.7586651285174919;0.754332564258746;9.117698628726131;95.86613314633948;4.835431205071165;0.0032085532024895276;0.6222841766978864;[SLC36A1, HVCN1]
GO:0001558;regulation of cell growth;5.0;0.5833093054345528;0.5818956645781967;7.6590836060266145;26.25041167864861;3.793137346993279;8.785776550476476E-4;0.4842222321850823;[CDA, CYFIP1, CPNE5, PPP2R1A, AKT1, SFN, NRP1, CDKN1A, IL17RB, CEACAM1, SGK1, HBEGF, CDKN2C, SIPA1, CTGF, CXCL16, TNR, S100A8, IGFBP7, TGFB1, CRIM1, INHBA, BCL6, DNM2, PSRC1, FBP1]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[EDNRB, C3AR1, IL1R1, IL1R2, BTK, PLA2G7, CD19, ELANE, LYN, BST1, CD28, FFAR2, IL17RB, TLR10, TLR7, PTGS2, IGKC, NLRP12, ZYX, CDH5, IGHG1, GHSR, S100A8, SUCNR1, CALCRL, C5AR1, TNFRSF11A, IGLV1-44, NLRP3, SELE, BCL6, IGKV3-20, TNFAIP6, CR2, CR1, CNR1, FCGR2B]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AQP9, AKT1, MEF2C, ABCB4, EGR1, JUP, NOX4, EZH2, ARG1, PTAFR, PTGS2, GNAI1, P2RY13, SLC8A1, CDH1, BLM, FOXO1, OSBPL7, TGFB1, INHBA, ALPL, SLC26A3, LRRK2, DNM2, COLEC12, P2RY6, RAD51, KLF5]
GO:0071404;cellular response to low-density lipoprotein particle stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;56.74958382123113;7.004484905440688;0.0018993574991869968;0.6813299963962409;[CD9]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, PTGS2, GPNMB, CDKN2C, PKN1, CDH5, DACH1, F2R, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, CTGF, FGF5, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, BCL6, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, RUNX2, BTC, TGFA, EGR1, EGR3, PTK2, BST1, CD28, CD24, NRP1, NRP2, PRL, CD3E, RHOG, PDCD1LG2, CEACAM6, GNAI2, CXCR2, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, LTF, MEIS2, TSHR, CD4]
GO:0060301;positive regulation of cytokine activity;8.0;1.0;0.875;9.628524252492122;129.14918693253554;9.777073627680469;0.004322507059909803;0.875;[NRP1]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, TRAT1, P2RX5, CD4]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, GNAI2, ELANE]
GO:0001523;retinoid metabolic process;8.0;0.7671156992804218;0.7585578496402109;9.193206181234276;47.546147792504925;5.334422371190153;0.0015913267778602078;0.6478026081386739;[LRP1, SDC2, DGAT2, ALDH1A1]
GO:0015808;L-alanine transport;11.0;0.8933024483968273;0.8790801765280758;9.567899630675686;156.4478742426539;7.8311634786251565;0.005236169556955925;0.8329150168128974;[SLC36A1]
GO:0034446;substrate adhesion-dependent cell spreading;6.0;1.0;0.8231203125901445;9.628524252492122;56.23121614310476;6.088194173566533;0.0018820081995007299;0.63447084575632;[NRP1]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[AKT1, MEF2C, RUNX2, GPNMB, FIGNL1, ALPL, LGR4]
GO:0015804;neutral amino acid transport;9.0;0.620063164412167;0.7062722073863725;8.558082840790709;67.63036776559719;6.113511981550823;0.002263527545735134;0.7088859122241795;[SLC36A1, SLC7A8]
GO:0010595;positive regulation of endothelial cell migration;9.0;0.8259837884571596;0.8092325194088689;9.488762310116963;298.6320589889849;5.2552850506314295;0.009994946262957053;0.664996147065328;[NRP1, NRP2, AKT1, ANXA3, PTGS2, TGFB1, PLK2]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[DENND1B, CD3G, CD3E, GRAP2, ICOSLG, BTK, HLA-DQB1, HHLA2, HLA-DQA1, TRAT1, BMX, CD4, CD28, HLA-DRA, LAT]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, IFNA2, TREM2, CD3E, GRM5, BANK1, HBEGF, TGFA, STAP1, LYN, TGFB1, ACE, GH1, CD4, CD24]
GO:0061740;protein targeting to lysosome involved in chaperone-mediated autophagy;12.0;1.0;0.9481203125901445;9.628524252492122;450.1958901409887;8.67846133901236;0.01506765129302233;0.8919372290569614;[LAMP2]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD274, HHLA2, CD3E, GRAP2, BTLA, AKT1, ICOSLG, LYN, PDCD1LG2, CD28, CD24]
GO:0046007;negative regulation of activated T cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;666.9675842715774;7.379178354882098;0.022322804813714202;0.7926125360964777;[CD274, ARG1, PDCD1LG2]
GO:1903830;magnesium ion transmembrane transport;9.0;0.8933024483968273;0.8428918493787028;9.56398573135455;114.73493840783627;6.943860283624253;0.0038400751337695784;0.7513499630073597;[SLC41A2]
GO:0048667;cell morphogenesis involved in neuron differentiation;6.0;0.811012628672052;0.7286266269261705;9.223059144383958;47.452274261266446;7.212124270218933;0.0015881849152503491;0.6919486831672181;[MEF2C, SLC1A3]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[CDKN1A, EHMT2, LRRK2, LAMP2, UPP1, SIK1, ATF3, SEH1L, FOXO1, GAS2L1]
GO:1903955;positive regulation of protein targeting to mitochondrion;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;662.5702871444865;6.311337724880743;0.022175631236180954;0.7380031166185408;[FZD5, RHOU]
GO:1990830;cellular response to leukemia inhibitory factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[TFRC, TLE4, PADI2, KLF5]
GO:0035767;endothelial cell chemotaxis;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;58.99646552848538;7.474488534686424;0.0019745586078665435;0.7572456912631272;[NR4A1, NRP1, EGR3]
GO:0015816;glycine transport;10.0;0.8436909121759173;0.837086467948879;9.466005322994347;184.47124825534323;7.474488534686424;0.006174086665761407;0.7974867031240476;[SLC36A1]
GO:0010248;establishment or maintenance of transmembrane electrochemical gradient;6.0;1.0;0.8231203125901445;9.628524252492122;27.942148572769092;7.212124270218933;9.351985664295021E-4;0.6919486831672181;[ATP1B2, ATP1B1]
GO:0032499;detection of peptidoglycan;6.0;0.9326813400603323;0.7894609826203107;9.571365838652174;162.92766460988707;9.083926447120524;0.005453042309114497;0.7876727335416686;[TREM2]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[EDNRB, GHSR, MEF2C, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, STAP1, NLRP3, ELANE, DEFA4, TNFRSF10C, DEFA1, SELE, ALPL, HMGB2, CXCL1, TREM2, CXCL2, CTSG, ARG1, PDCD1LG2, CEBPE, PTGS2, CNR1, NR1H2]
GO:0032497;detection of lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;150.00497270670016;8.390779266560578;0.005020531440782482;0.7522251544931926;[LY96, TREM2]
GO:0015813;L-glutamate transmembrane transport;11.0;0.8653626801206646;0.8651102923899945;9.551563211355994;441.01685901872065;6.8867018697843045;0.014760437381951706;0.7846152062148197;[SLC1A3, SLC7A11]
GO:2000661;positive regulation of interleukin-1-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;305.68887294206377;9.777073627680469;0.01023113147524637;0.875;[IL1R1]
GO:0035524;proline transmembrane transport;11.0;0.8653626801206646;0.8651102923899945;9.584072489921288;330.9290371701472;7.9853141584524145;0.011075897057287277;0.8407982897480031;[SLC36A1]
GO:0045445;myoblast differentiation;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;6.599019797332524;7.050676185779127E-4;0.587474179321389;[DTYMK, JAG1]
GO:0045446;endothelial cell differentiation;5.0;0.7866048967936545;0.6835434602577475;8.935377071932177;24.20171999872632;6.599019797332524;8.100097882234571E-4;0.6277151911823093;[JAG1]
GO:0071848;positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling;12.0;1.0;0.9481203125901445;9.628524252492122;1209.056277553609;9.083926447120524;0.04046602552971364;0.9126727335416687;[TNFRSF11A]
GO:0150018;basal dendrite development;7.0;1.0;0.8509193652572005;9.628524252492122;34.02047363004817;9.777073627680469;0.0011386346359592329;0.8509193652572005;[NRP1]
GO:0050806;positive regulation of synaptic transmission;7.0;0.6729672293956388;0.6874029799550199;8.679443697794976;101.54719009341356;4.857092701852345;0.0033986930658887844;0.599311311907839;[NRGN, TNR, KMO, SLC24A1, NLGN1, SLC1A3, RETN, PTGS2, PLK2]
GO:0048843;negative regulation of axon extension involved in axon guidance;12.0;1.0;0.9481203125901445;9.628524252492122;2931.023726508963;6.558197802812269;0.09809872637615838;0.7835068532133509;[NRP1]
GO:0048842;positive regulation of axon extension involved in axon guidance;12.0;1.0;0.9481203125901445;9.628524252492122;2927.4139206492227;7.8311634786251565;0.09797790942264722;0.8486063770733797;[NRP1]
GO:0060715;syncytiotrophoblast cell differentiation involved in labyrinthine layer development;5.0;1.0;0.7902410118609202;9.628524252492122;42.294635617598914;9.083926447120524;0.0014155633914202197;0.7547934328124444;[FZD5]
GO:0006930;substrate-dependent cell migration, cell extension;6.0;1.0;0.8231203125901445;9.628524252492122;58.56724312331254;7.474488534686424;0.001960192920240494;0.7053660038532718;[NRP1]
GO:0048846;axon extension involved in axon guidance;6.0;1.0;0.8231203125901445;9.628524252492122;104.6753254820163;7.697632086000634;0.003503388942206243;0.7167775754447168;[NRP1, NRP2, ALCAM]
GO:0060716;labyrinthine layer blood vessel development;5.0;1.0;0.7902410118609202;9.628524252492122;85.12843743852892;6.781341354126479;0.0028491721904478507;0.6370391240755715;[FZD5, AKT1]
GO:0060718;chorionic trophoblast cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;8.16763571524637;7.050676185779127E-4;0.6676932703116032;[FZD5, E2F7]
GO:0034138;toll-like receptor 3 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.474488534686424;0.013811191226989502;0.8303660038532719;[COLEC12, UNC93B1]
GO:0050921;positive regulation of chemotaxis;6.0;0.6417349323569144;0.6439877787686017;8.362857879160845;97.3409382187974;4.886724499458715;0.003257913601026301;0.5730276307483924;[NRP1, CXCL1, CXCL2, C3AR1, CCR6, SUCNR1, C5AR1, FPR2, PLA2G7, CXCR2, TGFB1, AZU1]
GO:0035589;G-protein coupled purinergic nucleotide receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;82.06132384088221;7.069023426578259;0.0027465186585576445;0.7365101867784198;[P2RY13, P2RY6, P2RY14, PTAFR, GPR171]
GO:0060982;coronary artery morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;32.54494596988572;7.57984905034425;0.0010892500530622757;0.710754145523778;[NRP1]
GO:0060627;regulation of vesicle-mediated transport;5.0;0.4849414530207067;0.5327117383712736;6.805163204878917;26.124861613659725;3.5745381104925467;8.743756073601922E-4;0.47304305706453076;[LGALS3, ACTN4, EPHA3, STXBP2, LYN, AZU1, NRP1, CEACAM1, PTAFR, GNAI2, NR1H2, IL13RA2, CD177, MAP2K2, TSC2, HGS, PRTN3, CD151, CORO1A, STAP1, TGFB1, SELE, MCTP1, ITGAM, LRRK2, SIRPB1, TBC1D9, DNM2, NLGN1, LRP1, PTX3, FCGR2B]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[ACE, TRHDE, ANPEP]
GO:0001569;branching involved in blood vessel morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;53.5045405888233;6.375876246018314;0.0017907488225476112;0.6769819729871445;[NRP1, ENG]
GO:0070306;lens fiber cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;24.20171999872632;7.212124270218933;8.100097882234571E-4;0.659069382437994;[TGFB1, SLC7A11]
GO:0015722;canalicular bile acid transport;10.0;1.0;0.9152410118609203;9.628524252492122;105.66982015532285;8.390779266560578;0.003536673783934714;0.8443458537639685;[ABCC3, AQP9]
GO:0015721;bile acid and bile salt transport;9.0;0.9326813400603323;0.8625812952104552;9.5544162803384;89.96332036720499;6.375876246018314;0.003010991370958501;0.722303232910233;[ABCC3, AQP9, CEACAM1, SLCO2B1]
GO:0032060;bleb assembly;6.0;1.0;0.8231203125901445;9.628524252492122;58.56724312331254;7.474488534686424;0.001960192920240494;0.7053660038532718;[EMP1]
GO:0035333;Notch receptor processing, ligand-dependent;8.0;1.0;0.875;9.628524252492122;50.748517158788495;7.8311634786251565;0.0016985071986044009;0.7754860644832351;[PSEN2]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[TFRC, SLC8A1, IL18RAP, CDH1, MYB, MEF2C, BLM, ABCB4, FOXO1, EGR1, TGFB1, JUP, EZH2, LRRK2, MAP4K1, ARG1, DNM2, FBP1, PCNA, PTAFR, PTGS2, GNAI1, RAD51, CD69]
GO:2000350;positive regulation of CD40 signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;186.95064880168647;9.777073627680469;0.006257069970731893;0.8509193652572005;[TREM2]
GO:0034241;positive regulation of macrophage fusion;7.0;1.0;0.8509193652572005;9.628524252492122;142.40946411816813;8.67846133901236;0.0047663166038382455;0.7947362817240173;[ADAM9]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[FOXO1, TGFB1, JAG1, SORT1]
GO:1902946;protein localization to early endosome;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;33.466755985853425;8.67846133901236;0.001120102204721561;0.7947362817240173;[NRP1]
GO:0002430;complement receptor mediated signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.57973408832269;218.73839564357212;7.212124270218933;0.007320977250414979;0.7650689957573628;[CR2, CR1, C5AR1, FPR1, C3AR1, FPR3, FPR2]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[TNFRSF11A, LGALS3]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, DUSP1, ANXA5, PTGS2, UNG, FLNA, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, DHCR24, BCL6, LRRK2, ADAMTS20, LRP1, NLRC4, LGALS3, TCL1A, EDNRB, BTC, POR, EPHA3, EGR3, BCL11B, PTK2, VNN1, CD28, NRP1, CEACAM6, GNAI2, CXCR2, GRINA, GHSR, C5AR1, PSEN2, CBX4, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF]
GO:0042098;T cell proliferation;6.0;0.7248374789738407;0.6855390520770648;9.081980546124052;51.294476028837884;6.343086423195323;0.0017167799506538708;0.647506047256038;[CD151]
GO:0070779;D-aspartate import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;425.4525215124219;8.390779266560578;0.014239513012610231;0.8615337942327104;[SLC1A3]
GO:0015734;taurine transport;7.0;1.0;0.8509193652572005;9.628524252492122;89.60636959924307;9.777073627680469;0.0029990445499896504;0.8509193652572005;[SLC6A6]
